Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial Meeting Abstract
| Authors: | Falchi, L.; Leslie, L. A.; Belada, D.; Kopeckova, K.; Offner, F.; Brody, J.; Canales, M.; García-Sancho, A. M.; Nijland, M.; Andersson, P. O.; Awan, F. T.; Christensen, J. H.; Drott, K.; Hellström, M.; Lewerin, C.; Narkhede, M.; Snauwaert, S.; Wahlin, B. E.; Rana, A.; Abbas, A.; Wang, L.; Dinh, M.; Vermaat, J. S. P.; Abrisqueta, P. |
| Abstract Title: | Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 1471 |
| End Page: | 1473 |
| Language: | English |
| ACCESSION: | WOS:000893223201197 |
| DOI: | 10.1182/blood-2022-158232 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
